Clinical Assessment of Weight Gain with Atypical Antipsychotics - Blonanserin vs Amisulpride
Background: Atypical antipsychotics appear to have the greatest potential to induce weight gain. Antipsychotic-induced weight gain is the one of main cause of non-compliance and discontinuation of treatment, often resulting in the relapse of psychosis. Objective: To compare the weight gain betw...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
JCDR Research and Publications Private Limited
2015-06-01
|
Series: | Journal of Clinical and Diagnostic Research |
Subjects: | |
Online Access: | https://jcdr.net/articles/PDF/6066/13007_CE[Ra1]_F(AK)_PF1(PAK)_PFA(AK)_PF2(PAG).pdf |
id |
doaj-13c69650d332419098ffdd8811a35a59 |
---|---|
record_format |
Article |
spelling |
doaj-13c69650d332419098ffdd8811a35a592020-11-25T04:04:44ZengJCDR Research and Publications Private LimitedJournal of Clinical and Diagnostic Research2249-782X0973-709X2015-06-0196FC07FC1010.7860/JCDR/2015/13007.6066Clinical Assessment of Weight Gain with Atypical Antipsychotics - Blonanserin vs AmisulprideTS DEEPAK0BN RAVEESH1BM PARASHIVAMURTHY2MS NARENDRA KUMAR3SUMANTH MALLIKARJUNA MAJGI4HN NAGESH5Postgraduate, Department of Pharmacology, MMC&RI, Mysore, India.Professor and Head, Department of Psychiatry, MMC&RI, Mysore, India.Professor and Head, Department of Pharmacology, MMC&RI, Mysore, India.Assistant Professor, Department of Psychiatry, MMC&RI, Mysore, India.Assistant Professor, Department of Community Medicine, MMC&RI, Mysore, India.Assistant Professor, Department of Pharmacology, MMC&RI, Mysore, India.Background: Atypical antipsychotics appear to have the greatest potential to induce weight gain. Antipsychotic-induced weight gain is the one of main cause of non-compliance and discontinuation of treatment, often resulting in the relapse of psychosis. Objective: To compare the weight gain between amisulpride and blonanserin treatment, in persons with psychosis. Materials and Methods: Fifty six subjects with psychosis attending psychiatry department at KR Hospital, Mysore were randomized into two equal groups. After obtaining informed consent, subjects of group I received amisulpride tablets 200 mg BD, and group II received blonanserin tablets 4 mg BD, for eight weeks. Body weight, Body Mass Index (BMI) and Waist Hip Ratio (WHR) were measured at baseline, 4 weeks and 8 weeks. Results: The mean weight gain with amisulpride at 4 weeks was 2.73 kg (5.21%) and at 8 weeks was 4.34 kg (8.28%) from the baseline. The mean weight gain with blonanserin at 4 weeks was 1.77 kg (3.46%) and at 8 weeks was 3.46 kg (6.75%) from the baseline. The mean BMI increase at 8 weeks with amisulpride was 1.66 ± 0.56 and with blonanserin was 1.34 ± 0.77. The mean WHR increase at 8 weeks with amisulpride was 0.036 ± 0.026 and with blonanserin was 0.029 ± 0.020. There was statistically significant increase in weight, BMI and WHR associated with both blonanserin and amisulpride at 8 weeks. But there was no statistically significant difference in those parameters between blonanserin and amisulpride, at eight weeks. Conclusion: Even though there was no significant difference in the weight gain caused by blonanserin, in comparison with amisulpride, both these drugs individually caused significant weight gain at 8 weeks, which is in contrast with the earlier studies, which needs to be further evaluated.https://jcdr.net/articles/PDF/6066/13007_CE[Ra1]_F(AK)_PF1(PAK)_PFA(AK)_PF2(PAG).pdfmetabolic adverse effectspsychosisrandomized controlled trial |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
TS DEEPAK BN RAVEESH BM PARASHIVAMURTHY MS NARENDRA KUMAR SUMANTH MALLIKARJUNA MAJGI HN NAGESH |
spellingShingle |
TS DEEPAK BN RAVEESH BM PARASHIVAMURTHY MS NARENDRA KUMAR SUMANTH MALLIKARJUNA MAJGI HN NAGESH Clinical Assessment of Weight Gain with Atypical Antipsychotics - Blonanserin vs Amisulpride Journal of Clinical and Diagnostic Research metabolic adverse effects psychosis randomized controlled trial |
author_facet |
TS DEEPAK BN RAVEESH BM PARASHIVAMURTHY MS NARENDRA KUMAR SUMANTH MALLIKARJUNA MAJGI HN NAGESH |
author_sort |
TS DEEPAK |
title |
Clinical Assessment of Weight Gain with Atypical Antipsychotics - Blonanserin vs Amisulpride |
title_short |
Clinical Assessment of Weight Gain with Atypical Antipsychotics - Blonanserin vs Amisulpride |
title_full |
Clinical Assessment of Weight Gain with Atypical Antipsychotics - Blonanserin vs Amisulpride |
title_fullStr |
Clinical Assessment of Weight Gain with Atypical Antipsychotics - Blonanserin vs Amisulpride |
title_full_unstemmed |
Clinical Assessment of Weight Gain with Atypical Antipsychotics - Blonanserin vs Amisulpride |
title_sort |
clinical assessment of weight gain with atypical antipsychotics - blonanserin vs amisulpride |
publisher |
JCDR Research and Publications Private Limited |
series |
Journal of Clinical and Diagnostic Research |
issn |
2249-782X 0973-709X |
publishDate |
2015-06-01 |
description |
Background: Atypical antipsychotics appear to have the
greatest potential to induce weight gain. Antipsychotic-induced
weight gain is the one of main cause of non-compliance and
discontinuation of treatment, often resulting in the relapse of
psychosis.
Objective: To compare the weight gain between amisulpride
and blonanserin treatment, in persons with psychosis.
Materials and Methods: Fifty six subjects with psychosis
attending psychiatry department at KR Hospital, Mysore were
randomized into two equal groups. After obtaining informed
consent, subjects of group I received amisulpride tablets 200
mg BD, and group II received blonanserin tablets 4 mg BD, for
eight weeks. Body weight, Body Mass Index (BMI) and Waist
Hip Ratio (WHR) were measured at baseline, 4 weeks and 8
weeks.
Results: The mean weight gain with amisulpride at 4 weeks was
2.73 kg (5.21%) and at 8 weeks was 4.34 kg (8.28%) from the
baseline. The mean weight gain with blonanserin at 4 weeks was
1.77 kg (3.46%) and at 8 weeks was 3.46 kg (6.75%) from the
baseline. The mean BMI increase at 8 weeks with amisulpride
was 1.66 ± 0.56 and with blonanserin was 1.34 ± 0.77. The mean
WHR increase at 8 weeks with amisulpride was 0.036 ± 0.026
and with blonanserin was 0.029 ± 0.020. There was statistically
significant increase in weight, BMI and WHR associated with
both blonanserin and amisulpride at 8 weeks. But there was no
statistically significant difference in those parameters between
blonanserin and amisulpride, at eight weeks.
Conclusion: Even though there was no significant difference
in the weight gain caused by blonanserin, in comparison with
amisulpride, both these drugs individually caused significant
weight gain at 8 weeks, which is in contrast with the earlier
studies, which needs to be further evaluated. |
topic |
metabolic adverse effects psychosis randomized controlled trial |
url |
https://jcdr.net/articles/PDF/6066/13007_CE[Ra1]_F(AK)_PF1(PAK)_PFA(AK)_PF2(PAG).pdf |
work_keys_str_mv |
AT tsdeepak clinicalassessmentofweightgainwithatypicalantipsychoticsblonanserinvsamisulpride AT bnraveesh clinicalassessmentofweightgainwithatypicalantipsychoticsblonanserinvsamisulpride AT bmparashivamurthy clinicalassessmentofweightgainwithatypicalantipsychoticsblonanserinvsamisulpride AT msnarendrakumar clinicalassessmentofweightgainwithatypicalantipsychoticsblonanserinvsamisulpride AT sumanthmallikarjunamajgi clinicalassessmentofweightgainwithatypicalantipsychoticsblonanserinvsamisulpride AT hnnagesh clinicalassessmentofweightgainwithatypicalantipsychoticsblonanserinvsamisulpride |
_version_ |
1724435442398396416 |